A new way to treat diabetes

Follicum identifies receptors in insulin-producing cells for potential new class of diabetes drugs
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
LUND, Sweden—Follicum AB announced in January that it has successfully mapped the receptors in insulin-producing cells that bind the company’s peptides. This new knowledge, the company says, represents an important milestone in the continued development of its diabetes project and opens the possibility of the identified receptors becoming potential drug targets for stimulating insulin secretion and reduction of diabetic complications.
 
The research was conducted in collaboration with Swiss proteomics specialist Dualsystems Biotech and aimed to identify receptors in a well-characterized insulin-producing cell line that bind the company’s peptides. The purpose of the experiments also included analysis on how the structure of the peptides can be optimized for the selection of novel drug candidates.
 
The experiments reportedly confirmed the existence of such receptors, thus suggesting that they could become new drug targets for Follicum’s peptides in diabetes treatment. To verify the hypothesis, the company will initiate detailed studies of the receptors in preclinical trials within the framework of its established cooperation with Prof. Jan Nilsson’s group at the Clinical Research Center in Lund University.
 
“With the new results from our diabetes project involving our peptide classes, we now look forward to conducting further studies to expand our knowledge, thereby paving the way for a potential development of a whole new class of diabetes drugs. We have recently strengthened our organization and we are looking forward to continued collaboration with Lund University,” said Follicum CEO Jan Alenfall.
 
The preclinical research is partly funded by a recent grant from the Novo Nordisk Foundation. Follicum is also a member of a major diabetes project, financed by the Swedish Foundation for Strategic Research. Follicum participates together with several leading companies within diabetes such as Novo Nordisk, Johnson & Johnson Innovation, Pfizer and Region Skåne/University Hospital of Skåne in Malmö.

Related Topics

Published In

Volume 14 - Issue 2 | February 2018

February 2018

February 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue